Compare Merck & Co., Inc. (MRK) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs uniQure N.V. Ordinary Shares — how do they compare? Merck & Co., Inc. trades at $150.1 (market cap $363.59B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Merck & Co., Inc. is far larger — about 250.8× uniQure N.V. Ordinary Shares's market cap, and Merck & Co., Inc. pays a 2.31% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MRK | QURE | |
|---|---|---|
Market Cap | $363.59B | $1.45B |
Volume | 8,036,558 | 3,323,243 |
Sector | Health | Health |
52-Week High | $156.43 | $70.59 |
52-Week Low | $82.49 | $9.03 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $410.35B | $707.46M |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.
The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
